[go: up one dir, main page]

PT3365321T - Zwiterião de solabegron e suas utilizações - Google Patents

Zwiterião de solabegron e suas utilizações

Info

Publication number
PT3365321T
PT3365321T PT168584514T PT16858451T PT3365321T PT 3365321 T PT3365321 T PT 3365321T PT 168584514 T PT168584514 T PT 168584514T PT 16858451 T PT16858451 T PT 16858451T PT 3365321 T PT3365321 T PT 3365321T
Authority
PT
Portugal
Prior art keywords
zwiterion
solabegron
solabegron zwiterion
Prior art date
Application number
PT168584514T
Other languages
English (en)
Original Assignee
B3Ar Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by B3Ar Therapeutics Inc filed Critical B3Ar Therapeutics Inc
Publication of PT3365321T publication Critical patent/PT3365321T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/16Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/26Radicals substituted by carbon atoms having three bonds to hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT168584514T 2015-10-23 2016-10-24 Zwiterião de solabegron e suas utilizações PT3365321T (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562245670P 2015-10-23 2015-10-23
US201562245656P 2015-10-23 2015-10-23
US201662345574P 2016-06-03 2016-06-03
US201662345357P 2016-06-03 2016-06-03
US201662345327P 2016-06-03 2016-06-03

Publications (1)

Publication Number Publication Date
PT3365321T true PT3365321T (pt) 2024-01-12

Family

ID=58557973

Family Applications (1)

Application Number Title Priority Date Filing Date
PT168584514T PT3365321T (pt) 2015-10-23 2016-10-24 Zwiterião de solabegron e suas utilizações

Country Status (11)

Country Link
US (5) US10065922B2 (pt)
EP (1) EP3365321B1 (pt)
CN (2) CN114230477A (pt)
CA (1) CA3001850A1 (pt)
DK (1) DK3365321T3 (pt)
ES (1) ES2967863T3 (pt)
FI (1) FI3365321T3 (pt)
IL (2) IL258856B2 (pt)
PL (1) PL3365321T3 (pt)
PT (1) PT3365321T (pt)
WO (1) WO2017070689A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
EA201791225A1 (ru) 2014-12-03 2017-12-29 Велисепт Терапьютикс, Инк. Композиции и способы применения солабегрона с модифицированным высвобождением при симптомах нижних мочевых путей
PT3365321T (pt) 2015-10-23 2024-01-12 B3Ar Therapeutics Inc Zwiterião de solabegron e suas utilizações
EP3446447B1 (en) * 2016-04-20 2024-02-28 Vasona Networks, Inc. Maximum sustainable encoding bit rates for video downloads
CN117695287A (zh) 2017-06-06 2024-03-15 住友制药(苏州)有限公司 使用维贝隆以治疗膀胱过度活动症
MX2021003980A (es) 2018-12-05 2021-07-21 Urovant Sciences Gmbh Vibegrón para el tratamiento de los síntomas de la vejiga hiperactiva.
CN111925294A (zh) * 2020-07-06 2020-11-13 济南大学 一种托特罗定帕莫酸盐及其制备方法

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL267508A (pt) 1960-07-26
DE2965655D1 (en) 1978-06-28 1983-07-21 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
GB8519154D0 (en) 1985-07-30 1985-09-04 Ici Plc Aromatic ethers
DE3934436A1 (de) 1989-06-01 1991-04-18 Thomae Gmbh Dr K 2-hydroxy-n-propylamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5061727A (en) 1990-05-04 1991-10-29 American Cyanamid Company Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles
NO179246C (no) 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
AU2737295A (en) 1994-06-09 1996-01-04 Glaxo Group Limited Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists
US5677346A (en) 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
WO1997015549A1 (en) 1995-10-26 1997-05-01 Tokyo Tanabe Company Limited PHENYLETHANOLAMINE COMPOUNDS USEFUL AS β3 AGONIST, PROCESS FOR PRODUCING THE SAME, AND INTERMEDIATES IN THE PRODUCTION OF THE SAME
US6123961A (en) 1996-09-25 2000-09-26 Bridge Pharma, Inc. Treating urinary incontinence with (R)-desethyloxybutynin and (R)-oxybutynin
GB9812709D0 (en) * 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
US20060240105A1 (en) 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
CA2348871C (en) 1998-11-02 2009-04-14 John G. Devane Multiparticulate modified release composition
DE19856167C1 (de) 1998-12-05 2000-05-04 Vetter & Co Apotheker Nadelschutzanordnung für Spritzen, Karpulen und dergleichen Injektionsinstrumente
GB9929297D0 (en) 1999-12-11 2000-02-02 Glaxo Group Ltd Process
US20030018061A1 (en) 2000-01-28 2003-01-23 Kohei Ogawa Novel remedies with the use of beta 3 agonist
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US6444685B1 (en) 2000-07-17 2002-09-03 Wyeth N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists
US6451814B1 (en) 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
US6395762B1 (en) 2000-07-17 2002-05-28 American Home Products Corporation Phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists
GB0102407D0 (en) * 2001-01-31 2001-03-14 Glaxo Group Ltd Process
US7709677B2 (en) 2001-01-31 2010-05-04 Glaxosmithkline Llc Process of preparing arylethanoldiamines
US7034053B2 (en) 2001-01-31 2006-04-25 Smithkline Beecham Corporation Phenethanolamine derivatives, compositions, and their use as agonists at atypical beta-adrenoreceptors
US20030190360A1 (en) 2001-03-13 2003-10-09 Baichwal Anand R. Chronotherapeutic dosage forms containing glucocorticosteroid and methods of treatment
WO2003024483A1 (fr) 2001-09-11 2003-03-27 Fujisawa Pharmaceutical Co., Ltd. Potentialisateur d'effets inhibiteurs sur la frequence des mictions et l'incontinence urinaire
TWI295669B (en) 2002-10-30 2008-04-11 Theravance Inc Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
EP1424079A1 (en) 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
EP1682183A2 (de) 2003-11-03 2006-07-26 Boehringer Ingelheim International Gmbh Pharmazeutische zusammensetzung enthaltend einen beta-3-adrenozeptor-agonisten und einem alpha antagonisten und/oder einen 5-alpha reduktase-hemmer
DE10352132A1 (de) 2003-11-04 2005-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Agonisten
DK1694354T3 (da) 2003-11-27 2009-10-26 Develogen Ag Fremgangsmåde til at forhindre og behandle diabetes ved anvendelse af neurturin
CN100582088C (zh) * 2003-12-23 2010-01-20 安斯泰来制药有限公司 氨基醇衍生物
WO2005065673A1 (en) 2003-12-31 2005-07-21 Actavis Group Hf Atomoxetine formulations
EP1550447A1 (en) 2004-01-02 2005-07-06 Schering Aktiengesellschaft Menstrual cycle control and improvement of conception rates in females
WO2005077364A1 (ja) 2004-02-18 2005-08-25 Yamanouchi Pharmaceutical Co., Ltd. ソリフェナシンの経皮投与製剤およびその経皮透過改善方法
WO2006042679A1 (de) 2004-10-18 2006-04-27 Boehringer Ingelheim International Gmbh Verwendung eines beta-3-agonisten zur behandlung von beschwerden der prostata und des unteren urogenitaltrakts
US8821927B2 (en) 2005-04-19 2014-09-02 Smithkline Beecham (Cork) Limited Pharmaceutical composition
EP1769792A1 (de) 2005-09-30 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co.KG Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden
ITMI20061581A1 (it) 2006-08-04 2008-02-05 Univ Bari Ligandi del recettore beta-3 adrenergico e loro uso in terapia
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
AU2008233232A1 (en) 2007-03-29 2008-10-09 Merck Sharp & Dohme Corp. Combination therapy for the treatment-of lower urinary tract symptoms
AU2008232419B2 (en) 2007-04-02 2013-06-20 Theracos, Inc. Benzylic glycoside derivatives and methods of use
GB0714790D0 (en) 2007-07-30 2007-09-12 Jagotec Ag Improvements in or relating to organic compounds
CA2704298C (en) 2007-11-02 2015-07-21 Astellas Pharma Inc. Pharmaceutical composition for treating overactive bladder
CA2719907A1 (en) 2008-04-04 2009-10-08 Merck Sharp & Dohme Corp. Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
EP2181707A1 (en) 2008-11-04 2010-05-05 Astellas Ireland Co., Ltd. Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
WO2010118291A2 (en) * 2009-04-10 2010-10-14 Auspex Pharmaceuticals, Inc. Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
EP2427194B1 (en) 2009-05-08 2014-10-08 Merck Sharp & Dohme Corp. Pyrrolidine-derived beta 3 adrenergic receptor agonists
US8586760B2 (en) 2009-06-15 2013-11-19 Auspex Pharmaceuticals, Inc. Aminothiazole modulators of beta-3-adrenoreceptor
WO2011025774A1 (en) 2009-08-27 2011-03-03 Merck Sharp & Dohme Corp. Novel pyrrolidine derived beta 3 adrenergic receptor agonists
EP2470021B1 (en) 2009-08-27 2014-10-22 Merck Sharp & Dohme Corp. Novel pyrrolidine derived beta 3 adrenergic receptor agonists
EP2485595A4 (en) 2009-10-07 2014-03-12 Merck Sharp & Dohme COMBINATION THERAPY WITH AN ADRENERGIC BETA-3 RECEPTOR AGONIST AND ANTIMIC CARCINU
CN102753170A (zh) 2009-12-15 2012-10-24 新陈代谢解决方案开发公司 治疗糖尿病及其它代谢性疾病的ppar节制的噻唑烷二酮和组合
WO2011084459A1 (en) 2009-12-15 2011-07-14 Metabolic Solutions Development Company Ppar-sparing thiazolidinediones and combinations for the treatment of obesity and other metabolic diseases
AU2010331926B2 (en) 2009-12-15 2014-03-27 Cirius Therapeutics, Inc. PPAR-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
US8748433B2 (en) 2010-04-30 2014-06-10 Merck Sharp & Dohme Corp. β3 adrenergic receptor agonists
NZ602921A (en) 2010-05-05 2016-01-29 Boehringer Ingelheim Int Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
US9907767B2 (en) * 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
EA030145B1 (ru) * 2010-08-03 2018-06-29 Велисепт Терапьютикс, Инк. Комбинации агонистов бета-3-адренергических рецепторов и антагонистов мускариновых рецепторов для лечения гиперактивности мочевого пузыря
WO2016004056A1 (en) 2014-07-03 2016-01-07 Velicept Therapeutics, Inc. Pharmaceutical combinations
WO2012154770A1 (en) 2011-05-10 2012-11-15 Theravida, Inc. Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder
JP2015509931A (ja) 2012-02-09 2015-04-02 アルセレックス,インコーポレイテッド 医薬的な組み合わせ
ES2394349B1 (es) 2012-08-29 2013-11-04 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar
EP2891493A4 (en) 2012-08-31 2016-05-18 Astellas Pharma Inc MEDICAL COMPOSITION ADMINISTERED ORALLY
US20150306170A1 (en) 2012-11-21 2015-10-29 Ferring B.V. Composition for immediate and extended release
HK1219268A1 (zh) 2013-02-26 2017-03-31 Xenoport, Inc. 1-(酰氧基)-烷基氨基甲酸酯化合物的制造方法
EA201691582A1 (ru) * 2014-02-07 2017-01-30 Оспекс Фармасьютикалз, Инк. Новые фармацевтические препараты
EA201791225A1 (ru) 2014-12-03 2017-12-29 Велисепт Терапьютикс, Инк. Композиции и способы применения солабегрона с модифицированным высвобождением при симптомах нижних мочевых путей
PT3365321T (pt) 2015-10-23 2024-01-12 B3Ar Therapeutics Inc Zwiterião de solabegron e suas utilizações
WO2017210696A1 (en) 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder
WO2017210700A1 (en) 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
JP2024513830A (ja) 2021-03-31 2024-03-27 ビースリーエーアール セラピューティクス、インク. 微粉化ソラベグロンの組成物およびその使用方法

Also Published As

Publication number Publication date
US20240124391A1 (en) 2024-04-18
CA3001850A1 (en) 2017-04-27
EP3365321A4 (en) 2019-06-05
HK1258038A1 (en) 2019-11-01
US20180370902A1 (en) 2018-12-27
CN108290824A (zh) 2018-07-17
DK3365321T3 (da) 2024-01-15
IL258856B1 (en) 2024-03-01
EP3365321A2 (en) 2018-08-29
ES2967863T3 (es) 2024-05-06
WO2017070689A3 (en) 2017-07-20
IL310527A (en) 2024-03-01
US12435026B2 (en) 2025-10-07
US11691944B2 (en) 2023-07-04
FI3365321T3 (fi) 2024-01-02
CN108290824B (zh) 2022-03-11
US10844004B2 (en) 2020-11-24
EP3365321B1 (en) 2023-12-13
US20170114005A1 (en) 2017-04-27
CN114230477A (zh) 2022-03-25
US20210317073A1 (en) 2021-10-14
US10065922B2 (en) 2018-09-04
PL3365321T3 (pl) 2024-03-25
IL258856B2 (en) 2024-07-01
WO2017070689A2 (en) 2017-04-27
US10221126B2 (en) 2019-03-05
US20190185414A1 (en) 2019-06-20
IL258856A (en) 2018-06-28

Similar Documents

Publication Publication Date Title
IL293377A (en) Hsd17b13 variants and uses thereof
FIC20230014I1 (fi) Foslevodopa ja foskarbidopa
IL280863A (en) Autotaxin inhibitors and uses thereof
EP3411412A4 (en) FIT-IMMUNOGLOBULIN TECHNOLOGY AND USES THEREOF
DK3405050T3 (da) Børnesikret snusbeholder
PL3265448T3 (pl) Proleki riluzolu i ich zastosowanie
DK3368534T3 (da) Valbenazin-ditosylat og polymorfer deraf
EP3334706A4 (en) PILLARARES AND USES THEREOF
EP3205103C0 (en) INTER AND INTRA UNIFICATION BLOCK COPY
DK3099172T3 (da) Modificeret biologisk bekæmpelsesmiddel og anvendelser deraf
EP3466394A4 (en) ASSISTANCE DEVICE FOR MARKET MOVEMENT
MA40933A (fr) Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
LT3394065T (lt) Tetrahidropiranilamino-pirolopirimidinonas ir jo panaudojimo būdai
DK3436823T3 (da) Antigen-array
EP3481952A4 (en) METHYLATION MARKERS IN THE TREATMENT OF LEUKEMIA AND USES THEREOF
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
DK3445708T3 (da) Stigbøjle
EP3402022A4 (en) GRAB WIRE
PT3365321T (pt) Zwiterião de solabegron e suas utilizações
PT3337506T (pt) Combinações e suas utilizações
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
EP3340806A4 (en) STEVIA EXTRACTS
DK3575238T3 (da) Pallecontainer
MA49905A (fr) Polyesteramines et polyesterquats